The litigation centers on allegations that GeneDx misled shareholders regarding the financial impact of its acquisition of Fabric. According to the complaint, company leadership repeatedly suggested that the integration would streamline operations and reduce the cost of goods sold through algorithmic optimization. Plaintiffs contend these representations were false, arguing that defendants were aware of, or recklessly disregarded, significant viability issues within Fabric that ultimately hindered business performance.

Investors who acquired shares during the specified period may be eligible for compensation through a contingency fee arrangement. Those interested in serving as a lead plaintiff must file a motion with the court by the August deadline. Participation as a lead plaintiff is not required to remain part of the potential class, and investors retain the right to select their own legal counsel. As of now, no class has been certified, meaning individuals are not represented by an attorney unless they actively retain one.